Henry Schein beats profit estimates but stock dips slightly on revenue miss
Henry Schein Inc. (HSIC) reported Q3 adjusted EPS of $1.56, beating estimates by $0.20, but revenue of $3.47B missed slightly. Shares fell 0.72% premarket. The company raised its full-year 2026 adjusted EPS guidance to $5.50-$5.56, with a midpoint above consensus. U.S. dental sales grew 8.6%, and adjusted EBITDA increased to $321M, up from $295M YoY.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise may attract short‑term buying, but the revenue miss could trigger profit‑taking.
Market read
First‑time earnings and guidance disclosure with material numbers; actionable for traders monitoring healthcare distribution stocks.
What to watch
Tariff refund assumptions and the modest 0.72% pre‑market dip indicate market caution.
Background
HSIC is a leading provider of dental and medical products; its quarterly results are closely watched by sector investors.
Ticker impact
HSIC reported Q3 EPS of $1.56 beating estimates, revenue of $3.47B missing consensus, and raised FY2026 EPS guidance to $5.50‑$5.56.
likely slight pressure as the market prices in the revenue shortfall despite the EPS beat and guidance lift
Investors weigh the revenue miss against the EPS beat and higher guidance; the net effect is modest negative bias.
Market effects
Dental and healthcare distribution sector may see mixed sentiment as HSIC's guidance lift could support peers, but revenue miss highlights demand softness.
U.S. healthcare supply chain stocks may experience slight volatility.
Limited to U.S. market; no broader macro impact.
Counterpoint
The revenue miss could signal underlying demand weakness, suggesting a deeper pullback despite guidance uplift.
Key entities
- companyHenry Schein Inc.
Healthcare solutions provider reporting Q3 2026 results.
